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Background: Gastroenteropancreatic neuroendocrine tumors have occasionally been described in association with
neurofibromatosis type 1, whereas an association with neurofibromatosis type 2 has never been reported.
Case presentation: This report refers to an Italian 69 year old woman with neurofibromatosis type 2 and a pancreatic
gastrinoma. In the past she had encephalic meningiomas, a tongue schwannoma and bilateral acoustic neurinomas.
She presented with weight loss and a long-term history of diarrhea, responsive to proton pump inhibitors. Upper
gastrointestinal endoscopy revealed peptic ulcer of the duodenal bulb. Blood tests were normal, except for the
elevation of plasma gastrin (1031 pg/ml; reference value <108) and chromogranin A (337 U/L; reference value
<36). After secretin stimulation testing, the plasma gastrin level rose to 3789 pg/ml. The abdomen magnetic
resonance imaging and gallium68-DOTATOC positron emission tomography scan demonstrated the presence of
a 1.2 x 2 cm lesion in the pancreatic head and a liver metastatis. Pancreatic endoscopic ultrasound with fine
needle aspiration revealed cytomorphologic features suggestive of pancreatic gastrinoma. Brain magnetic
resonance showed a pituitary microadenoma. There was no evidence of hyperparathyroidism. The genetic test
for multiple endocrine neoplasia type 1 syndrome mutation was negative.
Conclusion: This report focuses on the first case of coexistence of gastrinoma with neurofibromatosis type 2.
Although the clinical relevance of this association remains to be determined, our case report will surely give
cause for due consideration.
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Both gastroenteropancreatic neuroendocrine tumors (GEP
NET) and neurofibromatosis type 2 (NF2) are fairly rare
diseases [1,2]. GEP NET have occasionally been described
in association with neurofibromatosis type 1 (NF1) [3],
whereas an association with NF2 has never been reported.
Gastrinoma is a gastrin-secreting tumor usually located
in the duodenal wall or in the pancreas [4]. Chronic hyper-
gastrinemia causes gastric acid hypersecretion with conse-
quent peptic ulcer disease, diarrhea and gastroesophageal
reflux disease (Zollinger Ellison syndrome, ZES), usually
responsive to proton pump inhibitor (PPI) therapy. With
an incidence of 0.5-2/million population/year gastrinoma* Correspondence: sara.massironi@policlinico.mi.it
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reproduction in any medium, provided the ormay be sporadic or may develop in the setting of multiple
endocrine neoplasia type 1 (MEN1) syndrome [5-8]. The
tumors associated with MEN1 syndrome have a more
benign course than sporadic neuroendocrine tumors,
although more aggressive tumors have rarely been
described in association with MEN1 syndrome [9]. MEN1
is an autosomal dominant inherited disease, due to in-
activating mutations of the MEN1 gene, located on the
long arm of chromosome 11 (11q13) [10]. Diagnostic cri-
teria for MEN1 include the presence of at least two of the
three main MEN1 associated lesions (primary hyper-
parathyroidism, GEP NET and anterior pituitary tumors)
or the association of any typical MEN1-associated neo-
plasia and a positive familial history [11]. Diagnostic con-
firmation is achievable through MEN1 genetic testing.
According to available data, an association between
GEP NET and NF1 has already been reported and it is
well recognized that NF1 patients may develop NET,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Secretin stimulation test in the patient. Plasma gastrin
levels were measured at −30 and 0 time, and 2, 5, 10, 15, 20 and
30 minutes after intravenous secretin infusion (Secrelux 2U/kg,
Goldham-Bioglan, Zusmarhausen. Germany). The increase from 1031
to 3789 pg/ml was observed within ten minutes.
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and occasionally in the pancreas [15]. Gastric carcinoids
have also been described [16].
NF2 is an autosomal dominant inherited disease char-
acterized by the predisposition to develop tumors of the
central nervous system (CNS) [2]. NF2 is caused by mu-
tations of the NF2 gene that codes for an oncosuppres-
sor protein named merlin or schwannomin and is
located on chromosome 22 (22q12.2) [17]. A common
manifestation of the disease is the development of ves-
tibular schwannomas, tumors in other cranial nerves
and meningiomas, usually multifocal and intracranial,
but sometimes also spinal or intradural [18].
At present an association between GEP NET and NF2
has never been reported. The present case report refers
to a woman with NF2 and a pancreatic gastrinoma.
Case presentation
In 2011 an Italian 69 years old woman was referred to our
Gastrointestinal Unit due to an 8 years long history of
diarrhea, dyspepsia and weight loss. Diarrhea was respon-
sive to PPI. Two years before (2009) she was diagnosed
as having NF2 syndrome, according to internationally
accepted clinical criteria [19], based on the finding of
multiple encephalic meningiomas (partially removed by
surgery), a tongue schwannoma and bilateral acoustic
neurinomas. In addition, a non-functioning adrenal aden-
oma, has also been diagnosed. To investigate the cause of
diarrhea, the patient had already undergone both a colon-
oscopy, negative, and an upper gastrointestinal endoscopy,
which provided clear cut evidence of a duodenal bulb ul-
ceration; during the endoscopy the measurement of intra-
gastric pH was not performed, since the patient was on
PPI. After two weeks of PPI withdrawal laboratory tests
revealed a marked increase in plasma gastrin levels
(1051 pg/ml; reference value, r.v. <108), chromogranin A
(337 U/L; r.v. <36), glucagon (524 pg/ml; r.v. 25–250).
The liver, kidney, thyroid and parathyroid function tests
were normal. Moreover, secondary causes of hyper-
gastrinemia were excluded.
A secretin stimulation test (Secrelux 2U/Kg, Goldham-
Bioglan, Zusmarhausen. Germany) was performed and
showed a diagnostic increase of plasma gastrin levels
(from 1031 to 3789 pg/ml) within ten minutes from
the secretin injection (Figure 1). The patient underwent
Octreoscan® with the evidence of a hypercaptant pancre-
atic lesion and a second one in the right frontal area,
consistent with a meningiomatous lesion. Other imaging
studies included abdomen magnetic resonance (MR) and
Gallium-68-DOTATOC positron emission tomography
(PET) (Figure 2), which revealed a 1.2 × 2 cm nodular
lesion in the pancreatic head, a liver metastatis and, the
already known cerebral meningioma. After several months
the patient underwent pancreatic endoscopic ultrasoundwith fine needle aspiration, demonstrating cytomorpho-
logic features suggestive of pancreatic gastrinoma, with
well-differentiated cells expressing Chromogranin A,
synaptophysin and gastrin at immunohistochemistry.
Ki-67 index was 2% and no mitosis was found in the sample.
Due to the coexistence of a gastrinoma and an adrenal
adenoma, a brain and encephalic trunk MR (Figure 3)
was performed to investigate the possible presence of a
pituitary neoplasm: this revealed partial empty sella, the
residual meningiomatous lesions and a pituitary microa-
denoma, which resulted non functioning at hormonal
blood tests. There was no evidence of hyperparathyroid-
ism, but, given the presence of a pancreatic gastrinoma,
a pituitary and an adrenal adenoma, the patient under-
went genetic testing for MEN1 mutations, which was
negative. Genetic test for the CDKN1B gene was not
performed since the patient died because of massive
bleeding from a cerebral meningioma.
Conclusions
We have reported the first case report of the association
between NF2 and a pancreatic gastrinoma, although it
remains to be determined whether this association is
merely casual or not. The possible underlying patho-
genetic mechanisms need also elucidation.
The association between NF1 and GEP NET has already
been established. Several case reports and reviews of the
literature describe the coexistence of NF1 and neuroendo-
crine neoplasms, such as somatostatinomas, gastrinomas
[20], insulinomas [21] and gastric carcinoids [8-12]. In pa-
tients with NF1 NETs are most commonly localized in the
duodenum and in the peri-ampullary region. Although
Figure 2 Gallium-68-DOTATOC PET. Gallium68 PET detected the
presence of a nodular lesion of cm 1.2 x 2 in the pancreatic head
and a suspected liver metastatic lesion.
Figure 3 Brain MR with contrast. This T1-weighted image de-
tected multiple meningiomas enhancing intensely and homoge-
neously after administration of gadolinium.
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distinctive, they tend to be pure somatostatinomas [22,23]
or less frequently gastrinomas, whereas duodenal tumors
not associated with NF1 are frequently multihormonal,
but asymptomatic [24]. Other gastrointestinal manifesta-
tions can occur in several locations, in the form of gastro-
intestinal stromal tumors or ganglioneuromas [3]. Also an
association between NF1 and MEN2A is described in one
case report [25].
As concerns patients with NF2, schwannomas of the
intestinal tract are a possible complication [26], whereas
there are no data about coexistence with GEP NET and/
or MEN1 syndrome.
An increased occurrence of endocrine tumors, as well
as of other non endocrine tumors, including collageno-
mas, ependimomas, schwannomas and meningiomas has
been recently reported in patients with MEN1 [27-29].
Meningiomas arising in MEN1 setting are usually silent,thus the diagnosis is often late, with a mean interval of
18 years from the diagnosis of MEN1; they have a higher
incidence in patients with ZES in the MEN1 setting than
in patients with sporadic ZES [30].
The present report focuses on the first case of gastri-
noma in a NF2 patient. This patient might have a MEN1
like phenotype, as she showed the clinical features typ-
ical of MEN1 syndrome (pancreatic neuroendocrine
tumor, pituitary microadenoma and adrenal adenoma),
despite the absence of hyperparathyroidism and MEN1
gene mutations. The phenotype of MEN1 is broad and
different combinations of endocrine and non endocrine
manifestations have been described. About 30% MEN1
patients do not carry detectable MEN1 gene mutations
[31]. Patients without detectable mutations may have
mutations in introns or in the regulatory or untranslated
regions. Moreover, the polymerase chain reaction does
not reveal a large deletion causing the loss of a whole
exon. Recently, germ line mutations have been found in
the CDKN1B gene, encoding a cyclin dependent kinase
inhibitor protein that inhibits cell cycle progression
[32,33], even if only 1.6-2.8% of all tested cases of MEN1
have CDKN1B mutations [34]. The possible pathogenic
mechanisms underlying the dual development of gastri-
noma and NF2 remain to be elucidated. Interestingly, a
possible explanation for the high prevalence of neuro-
endocrine tumors in NF1 might be the loss of neurofibro-
min, a tumor suppressor protein, representing the main
product of the NF1 gene. Again, the mutation of the G
protein Ras, often seen in NF1 tumors, could promote
tumorigenesis due to a prolonged or persistent arrest in
the activated GTP loaded state. Recent studies have clearly
shown that also the tumor-suppressor protein merlin,
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merlin probably regulates angiogenesis to support
schwannoma growth, although the exact mechanisms are
still unexplored [36]. Angiogenesis is an important deter-
minant of tumor growth also in neuroendocrine neo-
plasms, so merlin could influence their development and
growth. Another possible explanation of the association
between NF2 and GEP NET may be the likely common
embryological origin of nervous and neuroendocrine cells
from the neural crest, although some authors have
recently suggested that the neuroendocrine system might
originate from the endoderm [37,38].
Overall, the possible pathogenic mechanisms underlying
the occurrence of both gastrinoma and NF2, which would
allow to discriminate between an actual connection and a
merely casual association, remain to be elucidated.
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